Shuwen Biotech Press Releases

Published on January 13, 2025 - 03:51 GMT

MammaTyper® Included in Leading Breast Cancer Guideline

Cerca Biotech’s innovative breast cancer molecular subtyping assay is recognized by leading professional associations in China BERLIN, GERMANY, January 13, 2025 /⁨EINPresswire.com⁩/ -- Cerca Biotech GmbH (“Cerca Biotech”) and Shuwen Biotech (“Shuwen”) …

Distribution channels: Banking, Finance & Investment Industry, Business & Economy ...
Published on July 30, 2024 - 10:42 GMT

Shuwen Biotech Announces NMPA Approval for Pre-eclampsia Point of Care Test

CercaTest RED Pre-eclampsia Test Approved for both Professional Use and Self-testing at Home CHINA, July 30, 2024 /⁨EINPresswire.com⁩/ -- Shuwen Biotech, an integrated in vitro diagnostic (IVD) company today announced that it has received approval from …

Distribution channels: Business & Economy, Companies ...
Published on March 25, 2024 - 09:22 GMT

Five MammaTyper® Studies Published in EBCC-14

Studies demonstrate superior performance and clinical benefits of MammaTyper® in HER2 testing BERLIN, GERMANY, March 25, 2024 /⁨EINPresswire.com⁩/ -- Cerca Biotech GmbH announces that in the 14th European Breast Cancer Conference (EBCC-14) in Milan, Italy …

Distribution channels: Business & Economy, Companies ...
Published on December 11, 2023 - 11:32 GMT

Study shows locally-performed MammaTyper® test provides accurate prediction of low RS score for breast cancer prognosis

The MammaTyper® test could obviate further testing with multigene signature prognostic assays for up to 70% of hormone receptor-positive breast cancer patients. BERLIN, GERMANY, December 11, 2023 /⁨EINPresswire.com⁩/ -- A seminal study presented at the …

Distribution channels: Business & Economy, Companies ...
Published on November 13, 2023 - 09:11 GMT

Cerca Biotech Announces CE Mark of RNXtract®

Cerca Biotech announced that it has obtained a CE mark for RNXtract®, its kit for nucleic acid extraction from FFPE tissues. BERLIN, GERMANY, November 13, 2023 /⁨EINPresswire.com⁩/ -- Cerca Biotech GmbH (“Cerca”), a Germany-based diagnostic company in …

Distribution channels: Business & Economy, Companies ...
Published on September 21, 2023 - 09:20 GMT

Cerca Biotech Announces ISO 13485:2016 Certification

BERLIN, GERMANY, September 21, 2023 /⁨EINPresswire.com⁩/ -- Cerca Biotech GmbH (“Cerca”), a Germany-based diagnostic company in oncology and women’s health, today announced that its quality management system (QMS) has achieved ISO 13485:2016 certification …

Distribution channels: Business & Economy, Companies ...
Published on March 7, 2023 - 07:58 GMT

Shuwen Biotech Acquires Triple-Negative Breast Cancer Subtyping Technology

"Fudan Subtyping" to be Commercialized to Enable Personalized Therapies of TNBC and Improve Treatment Outcome DEQING, CHINA, March 7, 2023 /⁨EINPresswire.com⁩/ -- On March 3 TNBC Day, Shuwen Biotech, an integrated in vitro diagnostic company …

Distribution channels: Banking, Finance & Investment Industry, Business & Economy ...
Published on November 22, 2022 - 06:30 GMT

Cerca Biotech Presented New Clinical Data on Breast Cancer Test at EBCC

Study shows that MammaTyper® may be a superior alternative to IHC for identifying Her2-low breast cancer especially for the newer Her2-targeted ADC therapies. BERLIN, GERMANY, November 22, 2022 /⁨EINPresswire.com⁩/ -- Cerca Biotech GmbH (“Cerca”), a …

Distribution channels: Banking, Finance & Investment Industry, Business & Economy ...
Published on November 16, 2022 - 06:00 GMT

New Multigene Breast Cancer Test Could Speed up Accurate Diagnosis for Women, Evidence Suggests

BERLIN, GERMANY, November 16, 2022 /⁨EINPresswire.com⁩/ -- Three new research studies have concluded that MammaTyper could provide a reliable, efficient, and reproducible alternative to the molecular subtyping of breast cancer tumours. Studies in the …

Distribution channels: Banking, Finance & Investment Industry, Beauty & Hair Care ...
Published on November 14, 2022 - 08:24 GMT

Cerca Biotech Showcase New Products in MEDICA

BERLIN, GERMANY, November 14, 2022 /⁨EINPresswire.com⁩/ -- Cerca Biotech GmbH (“Cerca”), a Germany-based diagnostic company in oncology and women’s health, announced showcase in MEDICA of its innovative products MammaTyper® and CercaTest® Pre-eclampsia …

Distribution channels: Banking, Finance & Investment Industry, Conferences & Trade Fairs ...
Published on April 27, 2022 - 12:08 GMT

Shuwen Biotech Announce CE Mark of qPCR Assay for ERBB2 Expression

CercaTest ERBB2 Assay and MammaTyper® may serve as novel companion diagnostics for anti-HER2 therapies targeting HER2-low cancer. BERLIN, GERMANY, April 27, 2022 /⁨EINPresswire.com⁩/ -- Shuwen Biotech, an integrated in vitro diagnostic company with …

Distribution channels: Business & Economy, Companies ...
Published on March 7, 2022 - 07:43 GMT

Shuwen Biotech Announce Agreement with Devyser to Commercialize Breast Cancer Tests in China

Shuwen Biotech will distribute, and offer testing services with, Devyser's BRCA NGS and other oncology kits in China DEQING, CHINA, March 7, 2022 /⁨EINPresswire.com⁩/ -- Shuwen Biotech, an integrated in vitro diagnostic company with focuses on breast …

Distribution channels: Business & Economy, Companies ...
Published on November 10, 2021 - 11:58 GMT

Cerca Biotech Acquires MammaTyper® for Molecular Classification of Breast Cancer

Cerca's Commercial Team Begins Worldwide Marketing of the PCR Test of MammaTyper® for Precision Subtyping of Breast Cancer FRANKFURT, GERMANY, November 10, 2021 /⁨EINPresswire.com⁩/ -- Cerca Biotech GmbH (“Cerca”), a Germany-based diagnostic company …

Distribution channels: Healthcare & Pharmaceuticals Industry, Media, Advertising & PR ...

Contact

Jay Z. Zhang
Cerca Biotech GmbH and Shuwen Biotech Co. Ltd.
+86 572 889 9881

email us here

LinkedIn YouTube

Share This Newsroom

Facebook Twitter LinkedIn

Company/Organization

Shuwen Biotech Co. Ltd.
9 Stewart St
Athens, Ohio, 45701
United States
05728899881

The Newsroom of Shuwen Biotech Co. Ltd.